-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talditercept Alfa in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talditercept Alfa in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talditercept Alfa in Spinal Muscular Atrophy (SMA) Drug...
-
Innovation Ranking
Innovation Ranking – SMA Solar Technology AG
SMA Solar Technology AG (SMA) is a renewable energy company. It develops, produces, and distributes photovoltaic inverters, choke coils, transformers, and monitoring and energy management systems for PV systems. It also offers intelligent energy management system and digital services, as well as solar power plant operation and maintenance. It serves customers in South America, Asia Pacific, North America, Europe, the Middle East, and Africa. Its R&D efforts focus on developing complete system solutions and digital business models. The company has...
-
Product Insights
Likelihood of Approval Analysis for Spinal Muscular Atrophy (SMA)
Overview How likely is it that the drugs in Spinal Muscular Atrophy (SMA) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is...
-
Product Insights
NewSpinal Muscular Atrophy (SMA) – Drugs In Development, 2024
Empower your strategies with our Spinal Muscular Atrophy (SMA) – Drugs In Development, 2024 report and make more profitable business decisions. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms...
-
Product Insights
NewSurvival Motor Neuron Protein – Drugs In Development, 2024
The Survival Motor Neuron Protein pipeline drugs market research report outlays comprehensive information on the Survival Motor Neuron Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System which include indications of Spinal Muscular Atrophy (SMA). It also reviews key players involved in Survival Motor Neuron Protein targeted therapeutics development with respective active and dormant...
-
Product Insights
NewGrowth/Differentiation Factor 8 – Drugs In Development, 2024
The Growth/Differentiation Factor 8 pipeline drugs market research report outlays comprehensive information on the Growth/Differentiation Factor 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Genetic Disorders, and Musculoskeletal Disorders which include indications of Spinal Muscular Atrophy (SMA), Neuromuscular Disorders, Obesity, Unspecified Metabolic Disorders, Duchenne Muscular Dystrophy, Osteogenesis Imperfecta, Osteoporosis, and Unspecified...
-
Product Insights
NewChloride Channel Protein 1 – Drugs In Development, 2024
The Chloride Channel Protein 1 pipeline drugs market research report outlays comprehensive information on the Chloride Channel Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Musculoskeletal Disorders, Immunology, and Genetic Disorders which include indications of Neuromuscular Disorders, Spinal Muscular Atrophy (SMA), Sarcopenia, Myasthenia Gravis, Charcot-Marie-Tooth Disease Type I, and Charcot-Marie-Tooth Disease Type...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Pancreatic Ductal Adenocarcinoma Drug Details: SLATE-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Breast Cancer Drug Details: SLATE-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Ovarian Cancer Drug Details: SLATE-001 is under...